IGC Announces Issuance of Patent for the Treatment method of Alzheimer’s Disease Employing THC

POTOMAC, Md., July 22, 2021–(Small business WIRE)–India Globalization Cash, Inc. (the “Firm”) (NYSE American: IGC) announced now that on July 20, 2021, the United States Patent and Trademark Business (“USPTO”) issued a patent (#11,065,225) for the treatment of Alzheimer’s ailment entitled “Ultra-Very low dose THC as a opportunity therapeutic and prophylactic agent for Alzheimer’s Sickness.”

The initial patent application was initiated by the College of South Florida (“USF”) and filed on August 1, 2016. On May possibly 25, 2017, IGC entered into an unique license agreement with USF with respect to the patent software and the related exploration conducted on Alzheimer’s sickness.

The granted patent relates to IGC’s proprietary formulation meant to support in the cure of persons dwelling with Alzheimer’s sickness. IGC’s proprietary formulation, IGC-Ad1, is the subject of the Company’s earlier-disclosed Period 1 clinical demo. The Enterprise just lately declared the completion of Cohort 3 in its placebo-managed Several Ascending Dose (MAD) period 1 demo for developing basic safety and tolerability of IGC-Advertisement1 that makes use of THC on clients struggling from Alzheimer’s disorder.

Forward-searching Statements:

This press launch includes ahead-wanting statements inside the that means of Area 21E of the Securities Trade Act of 1934. These forward-seeking statements are centered mostly on IGC’s expectations and are topic to various risks and uncertainties, particular of which are past IGC’s manage. Genuine effects could vary materially from these forward-searching statements as a end result of, amid other factors, the Company’s failure or incapacity to commercialise a single or far more of the Company’s items or systems, like the investigational new drug or formulation explained in this release, or failure to get hold of Food and drug administration approval for the investigational new drug screening success from human scientific trials that may well not be favorable or as expected standard financial disorders that are significantly less favorable than envisioned, such as as a end result of the ongoing COVID-19 pandemic the FDA’s typical placement pertaining to hashish- and hemp-based mostly items and other elements, a lot of of which are discussed in IGC’s SEC filings. IGC incorporates by reference the human demo disclosures and Hazard Factors identified in its Yearly Report on Kind 10-K submitted with the SEC on June 14, 2021, as if completely incorporated and restated herein. Considering these hazards and uncertainties, there can be no assurance that the forward-seeking information contained in this release will come about.

About IGC:

India Globalization Funds, Inc. (IGC) engages in the development of cannabinoid-based mostly therapies for indications this sort of as Alzheimer’s ailment and ache. It operates in two traces of small business, Infrastructure and Lifestyle Sciences and is headquartered in Potomac, MD.

www.igcinc.us, www.igcpharma.com, Twitter @IGCIR.

Look at supply variation on businesswire.com: https://www.businesswire.com/news/property/20210722005361/en/


Claudia Grimaldi / 301-983-0998